A Phase 4 interventional study of ketamine/midazolam and Ketofol in Emergence Delirium, sponsored by Cairo University. Recruiting at 2 sites in Egypt. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2023-09-15.
Sponsored by Cairo University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing ketamine in Emergence Delirium — 7 open to participants now, 8 under way, none of them phase 3. Ketamine · Emergence Delirium.
Among the 16 studies testing ketamine in Emergence Delirium, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 5 in phase 4, and was the 8th registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →7 of the 16 studies testing ketamine in Emergence Delirium are open now, in 3 countries. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 2–6
Ain Shams University · Sites in Egypt
Ages 3–16
Cairo University · Sites in Egypt
Ages 2–6 · Healthy volunteers
Iva Smiljanić · Sites in Croatia
Ages 3 mo–7 yrs
Cairo University · Sites in Egypt
Ages 2–5
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 3 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 4 5
First in 2012; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 90 across the 16 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 7 studies filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
3 of the studies testing ketamine in Emergence Delirium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519863Ain Shams UniversityThe Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients | 2026-11 |
| NCT07427446Kasr El Aini HospitalDexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium | 2026-12 |
| NCT07057193Zagazig UniversityEffect of Different Drugs on Emergency Delirium in Preschool Age Patient | 2027-01-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing ketamine in Emergence Delirium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An optimum recovery profile after AT includes a rapid, smooth awakening without emergence agitation (EA), stable vital signs and oxygenation, reduced postoperative nausea and vomiting (PONV), controlled postoperative pain, and patient or parents' satisfaction. Ketamine is a low-cost drug with a wide therapeutic window. Ketamine is a competitive N-methyl-D-aspartate receptor antagonist with good analgesic properties and periprocedural amnesia.
The ketamine/midazolam combination was administered in different ways with controversial results about their effect on the EA and recovery profile.
Ketofol, a mixture of ketamine and propofol, has been used in different favorable recovery profiles regarding postoperative EA and PONV.
This study aims to evaluate the effect of premedication with an intramuscular ketamine/ midazolam combination versus pre-extubation ketofol on the EA and the recovery profile.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ketamine/midazolam
Drug: Ketofol
Drug pages: KetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
premedication
Pre-extubation
incidence of Emergence agitation
Time frame: starting from time of PACU admission after recover from anesthesia till 6 hours postoperative
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Nov 2023, 3 months after the start.
Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 3 months is below that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketamine · Midazolam · Ketofol